The role of ferritin in liver disease assessment

The role of ferritin in liver disease assessment

Background. Ferritin is an important integral and diagnostic marker of liver diseases. In 1/3 of patients with nonalcoholic fatty liver disease (NAFLD), manifestations of hyperferritinemia are revealed. Increased ferritin level indicates the severity of the disease course and affects the prognosis.O...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. G. Radchenko, V. B. Grinevich, E. S. Ivanyuk, L. B. Lazebnik
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2023-11-01
Series:	Фармакоэкономика
Subjects:	nonalcoholic fatty liver disease nafld ferritin iron metabolism disorder systemic inflammation insulin resistance human placenta hydrolysate peptides laennec
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/895
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis
by: M. Imawari, et al.
Published: (2023-11-01)

Study of the effectiveness of the drug Laennek in case of liver damage by palm oil in rats
by: T. E. Bogacheva, et al.
Published: (2024-01-01)

Association of the p.I148m polymorphism in the <i>PNPLA3</i> gene with the severity of nonalcoholic fatty liver disease in various clinical groups
by: D. V. Sidorenko, et al.
Published: (2024-04-01)

The Role of the Liver in the Pathophysiology of PCOS: A Literature Review
by: Abrar Alhermi, et al.
Published: (2025-01-01)

Nonalcoholic fatty liver disease: cause or consequence of insulin resistance?
by: Ekaterina E. Mishina, et al.
Published: (2017-12-01)

Metabolic Syndrome in Adults with Nonalcoholic Fatty Liver Disease
by: Zhahid Hassan, et al.
Published: (2021-09-01)

Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease
by: K. A. Andreev, et al.
Published: (2022-01-01)

Association of insulin resistance and non-alcoholic fatty liver disease
by: Ekaterina E. Mishina, et al.
Published: (2021-01-01)

Limosilactobacillus mucosae FZJTZ26M3 prevents NAFLD in mice through modulation of lipid metabolism and gut microbiota dysbiosis
by: Danting Dang, et al.
Published: (2024-05-01)

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01)

A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease
by: Michelle Thuy Nguyen, et al.
Published: (2025-03-01)

Features of Glucose Homeostasis and Blood Lipid Spectrum in Patients with Nonalcoholic Fatty Liver Dis ease Depending on the Obesity Degree
by: Korniichuk I., et al.
Published: (2019-04-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)

Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease
by: Goran Hauser, et al.
Published: (2025-03-01)

Review of roles of RNA-binding proteins on NAFLD and the related pharmaceutical measures
by: Changjin Li, et al.
Published: (2025-05-01)

The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review
by: Mihaela Simona Popoviciu, et al.
Published: (2024-04-01)

The role of oxidized lipid species in insulin resistance and NASH in children
by: Nicola Santoro, et al.
Published: (2022-10-01)

The serum hepcidin and the hepcidin/ferritin ratio in NAFLD: a systematic review and meta-analysis
by: Jingmin Song, et al.
Published: (2025-02-01)

Frequency of insulin resistance among non-diabetic patients with non-alcoholic fatty liver disease using HOMA-IR: an experience of a tertiary care hospital in Karachi, Pakistan
by: Lubna Kamani, et al.
Published: (2025-04-01)

Triglycerides mediate the relationships of per- and poly-fluoroalkyl substance (PFAS) exposure with nonalcoholic fatty liver disease (NAFLD) risk in US participants
by: Wenying Qiao, et al.
Published: (2025-01-01)

Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus
by: Yu-Ming Cheng, et al.
Published: (2024-09-01)

Is nonalcoholic fatty liver disease associated with metabolic syndrome? An experience from a medical college of West Bengal, India
by: Sounak Sinha, et al.
Published: (2025-06-01)

Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders
by: O. A. Gromova, et al.
Published: (2021-02-01)

Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study
by: Farzad Salmanizadeh, et al.
Published: (2025-05-01)

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
by: Apollinariya V. Bogolyubova, et al.
Published: (2017-12-01)

Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
by: Yu-Ming Cheng, et al.
Published: (2025-04-01)

Excessive Iron Induces Macrophage Dysfunction in the Liver, Causing Adverse Pregnancy Outcomes in Mice
by: Sayaka Shimazaki, et al.
Published: (2025-06-01)

Non-pharmacological methods of treatment and rehabilitation of patients with non-alcoholic fatty liver disease
by: V. A. Akhmedov, et al.
Published: (2021-06-01)

Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups
by: Tatsuya Fukuda, et al.
Published: (2025-06-01)

Oxidative stress and inflammation in hemodialysis: a comparison of patients with or without advanced nonalcoholic fatty liver disease (NAFLD)
by: Vanja Kalacun, et al.
Published: (2025-12-01)

Urinary Ferritin as an Early Indicator of Tubular Injury in Diabetic Kidney Disease: Insights from NHANES and Clinical Cohorts
by: Huang B, et al.
Published: (2025-07-01)

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
by: Yue Wang, et al.
Published: (2025-02-01)

Identification of Interactive Genetic Loci Linked to Insulin Resistance in Metabolic Syndrome—An Update
by: Imadeldin Elfaki, et al.
Published: (2025-01-01)

Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content
by: Haoxiang Zhu, et al.
Published: (2025-01-01)

Association between triglyceride–glucose index and liver enzymes in adults with metabolic syndrome: a retrospective cross-sectional study
by: Raju Rana, et al.
Published: (2025-12-01)

Systematic analysis of the pharmacology of standardized extracts of human placenta
by: T. E. Bogacheva, et al.
Published: (2024-01-01)

Study on ferritin and liver injury in pediatric hemophagocytic lymphohistiocytosis associated with infection
by: Gailing Hao, et al.
Published: (2025-04-01)

Metabolic effects of ursodeoxycholic acid in patients with non-alcoholic fatty liver disease
by: V. A. Akhmedov
Published: (2024-04-01)

Association of Hepatic Fibrosis Measured by Transient Elastography with Ferritin Level of Patients with Transfusion Dependent Thalassemia in Iraq
by: zainab Gataa, et al.
Published: (2025-06-01)

LIVER DAMAGE IN PSORIASIS AND PSORIATIC ARTHRITIS: A LITERATURE REVIEW
by: Yu. L. Korsakova, et al.
Published: (2017-09-01)